Acquired resistance to MET kinase inhibition in MET-dependent non-small cell lung cancer cells mediated by a switch to EGFR dependency

Documenti analoghi

• TORquing metabolic reprogramming in cancer cells
  di: Pusapati, Raju, et al.
  Pubblicazione: (2016)
• MET-EGFR dimerization in lung adenocarcinoma is dependent on EGFR mtations and altered by MET kinase inhibition
  di: Ortiz-Zapater, Elena, et al.
  Pubblicazione: (2017)
• The coexistence of MET over-expression and an EGFR T790M mutation is related to acquired resistance to EGFR tyrosine kinase inhibitors in advanced non-small cell lung cancer
  di: Gou, Lan-Ying, et al.
  Pubblicazione: (2016)
• Discovery of a benzo[e]pyrimido-[5,4-b][1,4]diazepin-6(11H)-one as a Potent and Selective Inhibitor of Big MAP Kinase 1
  di: Deng, Xianming, et al.
  Pubblicazione: (2011)
• A case of EGFR mutant lung adenocarcinoma that acquired resistance to EGFR-tyrosine kinase inhibitors with MET amplification and epithelial-to-mesenchymal transition
  di: Miyoshi, Seigo, et al.
  Pubblicazione: (2015)